ARN25699
ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies.
For research use only. We do not sell to patients.
- Formula: C21H21N7O2
- Molecular Weight:403.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
GSK-3β |
DYRK1A |
Fyn-α |
ARN25699 (Compound 28) (0.1-10 μM) inhibits a subset of kinases associated with the pathogenesis of Alzheimer's disease[1].
ARN25699 (1-100 μM; 6 h) induces dose-dependent microtubule bundle formation in Tau0N4R-TM-tGFP U2OS cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 403.44
-
Formula C21H21N7O2
-
SMILES
O=C(N)C1=CC=CC(CNC2=NC(NC3=NNC(C4CCC4)=C3)=C(OC=C5)C5=N2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)